A disruption mechanism of the molecular clock in a MPTP mouse model of parkinson's disease

NeuroMolecular Medicine

Volumn 15, Issue 2, 2013, Pages 238-251

  Hayashi, Akane ^a   Matsunaga, Naoya ^a   Okazaki, Hiroyuki ^a   Kakimoto, Keisuke ^a   Kimura, Yoshinori ^a   Azuma, Hiroki ^a   Ikeda, Eriko ^a   Shiba, Takeshi ^a   Yamato, Mayumi ^a   Yamada, Ken Ichi ^a   Koyanagi, Satoru ^a   Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; AMP activated protein kinase; Circadian clock; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; CRYPTOCHROME 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; NUCLEAR RECEPTOR NR1D1; PER1 PROTEIN; PER2 PROTEIN; PROTEIN BMAL1; TRANSCRIPTION FACTOR CLOCK;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMAL1 GENE; BODY TEMPERATURE; CIRCADIAN RHYTHM; CLOCK GENE; CONTROLLED STUDY; CRY1 GENE; DEC1 GENE; DOPAMINERGIC NERVE CELL; GENE; HUMAN; HUMAN CELL; LOCOMOTION; MALE; MOLECULAR CLOCK; MOUSE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PER1 GENE; PER2 GENE; PRIORITY JOURNAL; REV ERB ALPHA GENE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ARNTL TRANSCRIPTION FACTORS; BODY TEMPERATURE; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHRONOBIOLOGY DISORDERS; CRYPTOCHROMES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NEUROBLASTOMA; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; PYRIMIDINES;

MUS;

EID: 84877743637     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-012-8214-x     Document Type: Article

References (81)

1. Alfinito, P. D.; Wang, S. P.; Manzino, L.; Rijhsinghani, S.; Zeevalk, G. D.; & Sonsalla, P. K. (2003). Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. Journal of Neuroscience, 23(34), 10982-10987.
2. Almirall, H.; Bautista, V.; Sanchez-Bahillo, A.; & Trinidad-Herrero, M. (2001). Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. Neurophysiologie Clinique, 31(3), 161-170.
3. Barcia, C.; De Pablos, V.; Bautista-Hernandez, V.; Sanchez-Bahillo, A.; Fernandez-Barreiro, A.; Poza, M.; et al. (2004). Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity. Journal of Neuroscience Methods, 134(1), 59-64.
4. Brooks, W. J.; Jarvis, M. F.; & Wagner, G. C. (1989). Astrocytes as a primary locus for the conversion MPTP into MPP+. Journal of Neural Transmission, 76(1), 1-12.
5. Bruguerolle, B. (2008). Clinical chronopharmacology in the elderly. Chronobiology International, 25(1), 1-15.
6. Bruguerolle, B.; & Simon, N. (2002). Biologic rhythms and Parkinson's disease: A chronopharmacologic approach to considering fluctuations in function. Clinical Neuropharmacology, 25(4), 194-201.
7. Cai, Y.; Liu, S.; Sothern, R. B.; Xu, S.; & Chan, P. (2010). Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. European Journal of Neurology, 17(4), 550-554.
8. Cheng, M. Y.; Bullock, C. M.; Li, C.; Lee, A. G.; Bermak, J. C.; Belluzzi, J.; et al. (2002). Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature, 417(6887), 405-410.
9. Chikahisa, S.; Fujiki, N.; Kitaoka, K.; Shimizu, N.; & Sei, H. (2009). Central AMPK contributes to sleep homeostasis in mice. Neuropharmacology, 57(4), 369-374.
10. Choi, J. S.; Park, C.; & Jeong, J. W. (2010). AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochemical and Biophysical Research Communications, 391(1), 147-151.
11. Ciruela, F.; Gomez-Soler, M.; Guidolin, D.; Borroto-Escuela, D. O.; Agnati, L. F.; Fuxe, K.; et al. (2011). Adenosine receptor containing oligomers: Their role in the control of dopamine and glutamate neurotransmission in the brain. Biochimica et Biophysica Acta, 1808(5), 1245-1255.
12. Cunha, R. A. (2005). Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signaling, 1(2), 111-134.
13. Curtis, A. M.; Cheng, Y.; Kapoor, S.; Reilly, D.; Price, T. S.; & Fitzgerald, G. A. (2007). Circadian variation of blood pressure and the vascular response to asynchronous stress. Proceedings of National Academy of Sciences USA, 104(9), 3450-3455.
14. Dauer, W.; & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39(6), 889-909.
15. de Mendonca, A.; Sebastiao, A. M.; & Ribeiro, J. A. (2000). Adenosine: Does it have a neuroprotective role after all? Brain Research Reviews, 33(2-3), 258-274.
16. Delle Donne, K. T.; & Sonsalla, P. K. (1994). Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. Journal of Pharmacology and Experimental Therapeutics, 271(3), 1320-1326.
17. Eastman, C. I.; Mistlberger, R. E.; & Rechtschaffen, A. (1984). Suprachiasmatic nuclei lesions eliminate circadian temperature and sleep rhythms in the rat. Physiology & Behavior, 32(3), 357-368.
18. Etchegaray, J. P.; Lee, C.; Wade, P. A.; & Reppert, S. M. (2003). Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature, 421(6919), 177-182.
19. Fastbom, J.; Pazos, A.; & Palacios, J. M. (1987). The distribution of adenosine A1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience, 22(3), 813-826.
20. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; et al. (1994). Nomenclature and classification of purinoceptors. Pharmacological Reviews, 46(2), 143-156.
21. Fredholm, B. B.; Irenius, E.; Kull, B.; & Schulte, G. (2001). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochemical Pharmacology, 61(4), 443-448.
22. Gekakis, N.; Staknis, D.; Nguyen, H. B.; Davis, F. C.; Wilsbacher, L. D.; King, D. P.; et al. (1998). Role of the CLOCK protein in the mammalian circadian mechanism. Science, 280(5369), 1564-1569.
23. Goldberg, N. R.; Haack, A. K.; Lim, N. S.; Janson, O. K.; & Meshul, C. K. (2011). Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neuroscience, 180, 256-271.
24. Gordon, J. L. (1986). Extracellular ATP: Effects, sources and fate. Biochemical Journal, 233(2), 309-319.
25. Hartmann, A.; Veldhuis, J. D.; Deuschle, M.; Standhardt, H.; & Heuser, I. (1997). Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: Ultradian secretory pulsatility and diurnal variation. Neurobiology of Aging, 18(3), 285-289.
26. Hastings, M. H. (1997). Central clocking. Trends in Neurosciences, 20(10), 459-464.
27. Hayashida, M.; Fukuda, K.; & Fukunaga, A. (2005). Clinical application of adenosine and ATP for pain control. Journal of Anesthesia, 19(3), 225-235.
28. Isojima, Y.; Okumura, N.; & Nagai, K. (2003). Molecular mechanism of mammalian circadian clock. Journal of Biochemistry, 134(6), 777-784.
29. Jackson-Lewis, V.; & Przedborski, S. (2007). Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols, 2(1), 141-151.
30. Jin, X.; Shearman, L. P.; Weaver, D. R.; Zylka, M. J.; de Vries, G. J.; & Reppert, S. M. (1999). A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell, 96(1), 57-68.
31. Knutsson, A. (2003). Health disorders of shift workers. Occupational Medicine, 53(2), 103-108.
32. Koyanagi, S.; Kuramoto, Y.; Nakagawa, H.; Aramaki, H.; Ohdo, S.; Soeda, S.; et al. (2003). A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Research, 63(21), 7277-7283.
33. Kudo, T.; Loh, D. H.; Truong, D.; Wu, Y.; & Colwell, C. S. (2011). Circadian dysfunction in a mouse model of Parkinson's disease. Experimental Neurology, 232(1), 66-75.
34. Kuhn, K.; Wellen, J.; Link, N.; Maskri, L.; Lubbert, H.; & Stichel, C. C. (2003). The mouse MPTP model: Gene expression changes in dopaminergic neurons. European Journal of Neuroscience, 17(1), 1-12.
35. Kume, K.; Zylka, M. J.; Sriram, S.; Shearman, L. P.; Weaver, D. R.; Jin, X.; et al. (1999). mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell, 98(2), 193-205.
36. Lamia, K. A.; Sachdeva, U. M.; DiTacchio, L.; Williams, E. C.; Alvarez, J. G.; Egan, D. F.; et al. (2009). AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science, 326(5951), 437-440.
37. Lau, Y. S.; & Mouradian, M. M. (1993). Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist. Journal of Neurochemistry, 60(2), 768-771.
38. Liu, S.; Chen, X. M.; Yoda, T.; Nagashima, K.; Fukuda, Y.; & Kanosue, K. (2002). Involvement of the suprachiasmatic nucleus in body temperature modulation by food deprivation in rats. Brain Research, 929(1), 26-36.
39. Maruyama, A.; & Fujio, T. (2001). ATP production from adenine by a self-coupling enzymatic process: high-level accumulation under ammonium-limited conditions. Bioscience, Biotechnology, and Biochemistry, 65(3), 644-650.
40. Matz, H.; & Hertz, L. (1989). Adenosine metabolism in neurons and astrocytes in primary cultures. Journal of Neuroscience Research, 24(2), 260-267.
41. Menza, M.; Dobkin, R. D.; Marin, H.; & Bienfait, K. (2010). Sleep disturbances in Parkinson's disease. Movement Disorders, 25(Suppl 1), S117-S122.
42. Michel, P. P.; Marien, M.; Ruberg, M.; Colpaert, F.; & Agid, Y. (1999). Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. Journal of Neurochemistry, 72(5), 2074-2082.
43. Mihaylova, M. M.; & Shaw, R. J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology, 13(9), 1016-1023.
44. Miyasaki, J. M.; Martin, W.; Suchowersky, O.; Weiner, W. J.; & Lang, A. E. (2002). Practice parameter: initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 58(1), 11-17.
45. Monge, A.; Viselli, F.; Stocchi, F.; Barbato, L.; Bolner, A.; Modugno, N.; et al. (2004). Variation in the dopaminergic response during the day in Parkinson disease. Clinical Neuropharmacology, 27(3), 116-118.
46. Monteleone, P.; & Maj, M. (2008). The circadian basis of mood disorders: Recent developments and treatment implications. European Neuropsychopharmacology, 18(10), 701-711.
47. Moore, R. Y.; & Silver, R. (1998). Suprachiasmatic nucleus organization. Chronobiology International, 15(5), 475-487.
48. Nagashima, K.; Matsue, K.; Konishi, M.; Iidaka, C.; Miyazaki, K.; Ishida, N.; et al. (2005). The involvement of Cry1 and Cry2 genes in the regulation of the circadian body temperature rhythm in mice. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 288(1), R329-R335.
49. Ng, C. H.; Guan, M. S.; Koh, C.; Ouyang, X.; Yu, F.; Tan, E. K.; et al. (2012). AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in drosophila models of Parkinson's disease. The Journal of Neuroscience, 32(41), 14311-14317.
50. Ohdo, S.; Koyanagi, S.; Matsunaga, N.; & Hamdan, A. (2011). Molecular basis of chronopharmaceutics. Journal of Pharmaceutical Sciences, 100(9), 3560-3576.
51. Ohdo, S.; Koyanagi, S.; Suyama, H.; Higuchi, S.; & Aramaki, H. (2001). Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nature Medicine, 7(3), 356-360.
52. 2A adenosine receptors: An apparent paradox. Drug Development Research, 45, 387-393.
53. Pahwa, R.; Factor, S. A.; Lyons, K. E.; Ondo, W. G.; Gronseth, G.; Bronte-Stewart, H.; et al. (2006). Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7), 983-995.
54. Ponsen, M. M.; Stoffers, D.; Booij, J.; van Eck-Smit, B. L.; Wolters, E. C.; & Berendse, H. W. (2004). Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Annals of Neurology, 56(2), 173-181.
55. Preitner, N.; Damiola, F.; Lopez-Molina, L.; Zakany, J.; Duboule, D.; Albrecht, U.; et al. (2002). The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell, 110(2), 251-260.
56. Ransom, B. R.; Kunis, D. M.; Irwin, I.; & Langston, J. W. (1987). Astrocytes convert the Parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neuroscience Letters, 75(3), 323-328.
57. Refinetti, R.; Kaufman, C. M.; & Menaker, M. (1994). Complete suprachiasmatic lesions eliminate circadian rhythmicity of body temperature and locomotor activity in golden hamsters. Journal of Comparative Physiology A, 175(2), 223-232.
58. Reichmann, H.; Schneider, C.; & Lohle, M. (2009). Non-motor features of Parkinson's disease: Depression and dementia. Parkinsonism & Related Disorders, 15(Suppl 3), S87-S92.
59. Reppert, S. M.; & Weaver, D. R. (2002). Coordination of circadian timing in mammals. Nature, 418(6901), 935-941.
60. Ripperger, J. A.; Shearman, L. P.; Reppert, S. M.; & Schibler, U. (2000). CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes & Development, 14(6), 679-689.
61. Ronnett, G. V.; Ramamurthy, S.; Kleman, A. M.; Landree, L. E.; & Aja, S. (2009). AMPK in the brain: Its roles in energy balance and neuroprotection. Journal of Neurochemistry, 109(Suppl 1), 17-23.
62. Rozas, G.; Lopez-Martin, E.; Guerra, M. J.; & Labandeira-Garcia, J. L. (1998). The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. Journal of Neuroscience Methods, 83(2), 165-175.
63. Ruby, N. F.; Dark, J.; Burns, D. E.; Heller, H. C.; & Zucker, I. (2002). The suprachiasmatic nucleus is essential for circadian body temperature rhythms in hibernating ground squirrels. Journal of Neuroscience, 22(1), 357-364.
64. Rudolphi, K. A.; Schubert, P.; Parkinson, F. E.; & Fredholm, B. B. (1992). Neuroprotective role of adenosine in cerebral ischaemia. Trends in Pharmacological Sciences, 13(12), 439-445.
65. Sakamoto, K.; Nagase, T.; Fukui, H.; Horikawa, K.; Okada, T.; Tanaka, H.; et al. (1998). Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. Journal of Biological Chemistry, 273(42), 27039-27042.
66. Sato, T. K.; Yamada, R. G.; Ukai, H.; Baggs, J. E.; Miraglia, L. J.; Kobayashi, T. J.; et al. (2006). Feedback repression is required for mammalian circadian clock function. Nature Genetics, 38(3), 312-319.
67. Shinohara, A.; Koyanagi, S.; Hamdan, A. M.; Matsunaga, N.; Aramaki, H.; & Ohdo, S. (2008). Dosing schedule-dependent change in the disruptive effects of interferon-alpha on the circadian clock function. Life Sciences, 83(15-16), 574-580.
68. Smeyne, R. J.; & Jackson-Lewis, V. (2005). The MPTP model of Parkinson's disease. Molecular Brain Research, 134(1), 57-66.
69. Stiasny-Kolster, K.; Doerr, Y.; Moller, J. C.; Hoffken, H.; Behr, T. M.; Oertel, W. H.; et al. (2005). Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain, 128, 126-137.
70. Stiasny-Kolster, K.; Mayer, G.; Schafer, S.; Moller, J. C.; Heinzel-Gutenbrunner, M.; & Oertel, W. H. (2007). The REM sleep behavior disorder screening questionnaire - A new diagnostic instrument. Movement Disorders, 22(16), 2386-2393.
71. Takahashi, J. S.; Hong, H. K.; Ko, C. H.; & McDearmon, E. L. (2008). The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nature Reviews Genetics, 9(10), 764-775.
72. Terazono, H.; Mutoh, T.; Yamaguchi, S.; Kobayashi, M.; Akiyama, M.; Udo, R.; et al. (2003). Adrenergic regulation of clock gene expression in mouse liver. Proceedings of National Academy of Sciences USA, 100(11), 6795-6800.
73. Torres-Farfan, C.; Abarzua-Catalan, L.; Valenzuela, F. J.; Mendez, N.; Richter, H. G.; Valenzuela, G. J.; et al. (2009). Cryptochrome 2 expression level is critical for adrenocorticotropin stimulation of cortisol production in the capuchin monkey adrenal. Endocrinology, 150(6), 2717-2722.
74. Ueda, H. R.; Hayashi, S.; Chen, W.; Sano, M.; Machida, M.; Shigeyoshi, Y.; et al. (2005). System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nature Genetics, 37(2), 187-192.
75. Ukai-Tadenuma, M.; Yamada, R. G.; Xu, H.; Ripperger, J. A.; Liu, A. C.; & Ueda, H. R. (2011). Delay in feedback repression by cryptochrome 1 is required for circadian clock function. Cell, 144(2), 268-281.
76. Um, J. H.; Pendergast, J. S.; Springer, D. A.; Foretz, M.; Viollet, B.; Brown, A.; et al. (2011). AMPK regulates circadian rhythms in a tissue- and isoform-specific manner. PLoS One, 6(3), e18450.
77. Um, J. H.; Yang, S.; Yamazaki, S.; Kang, H.; Viollet, B.; Foretz, M.; et al. (2007). Activation of 5′-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. Journal of Biological Chemistry, 282(29), 20794-20798.
78. Vieira, E.; Nilsson, E. C.; Nerstedt, A.; Ormestad, M.; Long, Y. C.; Garcia-Roves, P. M.; et al. (2008). Relationship between AMPK and the transcriptional balance of clock-related genes in skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism, 295(5), E1032-E1037.
79. Vingtdeux, V.; Davies, P.; Dickson, D. W.; & Marambaud, P. (2011). AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathologica, 121(3), 337-349.
80. Wardas, J. (2002). Neuroprotective role of adenosine in the CNS. Polish Journal of Pharmacology, 54(4), 313-326.
81. Wu, Y.; Li, X.; Zhu, J. X.; Xie, W.; Le, W.; Fan, Z.; et al. (2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals, 19(3), 163-174.